You are here: Industry Insights > Duchenne

News List

Immunoforge's 'PF1801' Is Designated as Orphan Drug by FDA prnasia
January 29, 2021
Immunoforge announced that their new drug candidate PF1801 has been designated as the FDA orphan drug for treatment of the Duchenne muscular dystrophy on January 25.
FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation worldpharmanews
December 17, 2019
The U.S. Food and Drug Administration today granted accelerated approval to Vyondys 53 (golodirsen) injection to treat Duchenne muscular dystrophy (DMD) patients who ...
Cheaper drug just as effective protecting heart in Duchenne muscular dystrophy worldpharmanews
September 27, 2019
A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in preserving cardiovascular function in boys with ...
Evox bags grant from Duchenne UK to engineer exosomes pharmatimes
November 14, 2018
Evox Therapeutics has secured £655,000 in funding from Duchenne UK, to support exploration of its exosome-based therapeutic platform for the condition.
Duchenne drug poised to cost $35,000 but with major catch pharmafiles
May 10, 2017
For those that have not followed the story, Emflaza was successfully taken through the FDA regulatory process by Marathon as the first new treatment for Duchenne muscular dystrophy.
FDA Approves Drug to Treat Duchenne Muscular Dystrophy americanpharmaceuticalreview
February 13, 2017
The U.S. Food and Drug Administration has approved Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD),